FULGENT GENETICS INC (FLGT) — insider trading
Health Care · NASDAQ
FULGENT GENETICS INC (FLGT) has 26 reported SEC Form 4 insider transactions in our data, including 8 open-market sales among the most recent 26 (latest 2026-09-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Xie Jian | Officer (President and COO) | Open-market sale | 2,127 | $19.66 | $41.8K | Form 4 |
| 2026-09-02 | Gao Hanlin | Officer (Chief Scientific Officer) | Open-market sale | 1,673 | $19.66 | $32.9K | Form 4 |
| 2026-09-01 | Hsieh Ming | Director, Officer (Chief Executive Officer), 10% owner | Shares withheld for taxes / exercise cost | 4,392 | $19.59 | $86.0K | Form 4 |
| 2026-09-01 | Kim Paul | Officer (CFO and Treasurer) | Shares withheld for taxes / exercise cost | 2,087 | $19.59 | $40.9K | Form 4 |
| 2026-08-27 | Gao Hanlin | Officer (Chief Scientific Officer) | Open-market sale | 939 | $19.91 | $18.7K | Form 4 |
| 2026-08-27 | Xie Jian | Officer (President and COO) | Open-market sale | 1,193 | $19.91 | $23.7K | Form 4 |
| 2026-08-26 | Kim Paul | Officer (CFO and Treasurer) | Shares withheld for taxes / exercise cost | 1,168 | $19.81 | $23.1K | Form 4 |
| 2026-08-26 | Hsieh Ming | Director, Officer (Chief Executive Officer), 10% owner | Shares withheld for taxes / exercise cost | 2,949 | $19.81 | $58.4K | Form 4 |
| 2026-07-26 | Gao Hanlin | Officer (Chief Scientific Officer) | Shares withheld for taxes / exercise cost | 1,645 | $19.67 | $32.4K | Form 4 |
| 2026-07-26 | Xie Jian | Officer (President and COO) | Shares withheld for taxes / exercise cost | 4,361 | $19.67 | $85.8K | Form 4 |
| 2026-07-26 | Kim Paul | Officer (CFO and Treasurer) | Shares withheld for taxes / exercise cost | 2,747 | $19.67 | $54.0K | Form 4 |
| 2026-06-02 | Gao Hanlin | Officer (Chief Scientific Officer) | Open-market sale | 1,688 | $17.89 | $30.2K | Form 4 |
| 2026-06-02 | Xie Jian | Officer (President and COO) | Open-market sale | 2,146 | $17.89 | $38.4K | Form 4 |
| 2026-06-01 | Hsieh Ming | Director, Officer (Chief Executive Officer), 10% owner | Shares withheld for taxes / exercise cost | 4,392 | $18.09 | $79.5K | Form 4 |
| 2026-06-01 | Kim Paul | Officer (CFO and Treasurer) | Shares withheld for taxes / exercise cost | 2,087 | $18.09 | $37.8K | Form 4 |
| 2026-05-27 | Gao Hanlin | Officer (Chief Scientific Officer) | Open-market sale | 945 | $17.60 | $16.6K | Form 4 |
| 2026-05-27 | Xie Jian | Officer (President and COO) | Open-market sale | 1,201 | $17.60 | $21.1K | Form 4 |
| 2026-05-26 | Kim Paul | Officer (CFO and Treasurer) | Shares withheld for taxes / exercise cost | 1,168 | $17.67 | $20.6K | Form 4 |
| 2026-05-26 | Hsieh Ming | Director, Officer (Chief Executive Officer), 10% owner | Shares withheld for taxes / exercise cost | 2,949 | $17.67 | $52.1K | Form 4 |
| 2026-05-14 | GROVES REGINA E | Director | Grant / award / vesting | 11,117 | — | $0 | Form 4 |
| 2026-05-14 | Dong Linda | Director | Grant / award / vesting | 11,117 | — | $0 | Form 4 |
| 2026-05-14 | Nohaile Michael | Director | Grant / award / vesting (derivative) | 8,426 | — | $0 | Form 4 |
| 2026-05-14 | Nohaile Michael | Director | Grant / award / vesting | 5,558 | — | $0 | Form 4 |
| 2026-04-26 | Kim Paul | Officer (CFO and Treasurer) | Shares withheld for taxes / exercise cost | 2,747 | $16.31 | $44.8K | Form 4 |
| 2026-04-26 | Xie Jian | Officer (President and COO) | Shares withheld for taxes / exercise cost | 4,361 | $16.31 | $71.1K | Form 4 |
| 2026-04-26 | Gao Hanlin | Officer (Chief Scientific Officer) | Shares withheld for taxes / exercise cost | 1,645 | $16.31 | $26.8K | Form 4 |
Ask the chat about FLGT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: FULGENT GENETICS INC (FLGT).
Last updated 2026-09-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.